U.S. Coronavirus: Experts worry that the increase in Covid-19’s diversified fuel may be weeks, but the case will decline again by summer.

Some experts predicted on Tuesday that the first infectious B1.7.7 variant has just been discovered in the UK, which is likely to increase in other cases a few times a week.

“If we had expected, more waves could have occurred in April or May,” Trevor Bedford of the University of Washington and Fred Hutchinson Cancer Research Center said during a center-sponsored briefing. “But I still suspect that things will get under control in the summer, and there will be very little virus spread.”

The increase in prognosis is the same reason why many experts highlight the need to double safety measures such as facial masks, social distance and avoid crowded areas. Helping fewer cases will also reduce the likelihood of further spread and mutation of the virus, experts said.

Nonetheless, an attached forecast by the Centers for Disease Control and Prevention on Wednesday said that by March 20, U.S. Coronavirus deaths are estimated at 526,000 to 548,000. An earlier forecast, released in February, estimated 559,000 deaths as of March 13.

Vaccinating as many people as possible will go a long way in slowing down further growth – and will soon gain strength in the vaccine arsenal.

Johnson and Johnson’s single-dose Covid-19 vaccine is available in the U.S. The Food and Drug Administration has met the requirements for authorization of emergency use, or EUA, the agency said in an analysis Wednesday.

Effectiveness of Johnson & Johnson vaccine against moderate to severe / severe / severe Covid-19 in all geographic areas, 66.9% at least 14 days after single dose vaccination and at least 28 days after vaccination, stated in FDA vaccine analysis and related biological products advisory committee, FDA. Independent group of consultants.

According to a 62-page briefing document released by the FDA on Wednesday, Johnson & Johnson’s vaccine analysis does not specifically support the safety profile of anyone who would prevent the EUA from issuing.

The advisory committee meets on Friday and will consider the documents and make recommendations on whether Johnson and Johnson’s vaccines should be authorized.

Is it time to delay the second dose of coronavirus vaccine?
With the emergency access pending approval, the Biden administration is preparing rollout plans for 30 million to 4 million doses of the Johnson and Johnson vaccine next week, said Jeff Zints, White House Covid-19 response coordinator.

White House press secretary Jane Sasaki said the administration was surprised when Johnson and Johnson were told they were behind in manufacturing. The initial dose is expected to be close to 10 million, CNN noted.

“We will continue to work with them to make sure it happens as quickly as possible,” Pasaki said of Johnson and Johnson.

Still, new, infectious types “make it difficult to stop the fourth wave together,” said Dr. Fred Hutchinson, an infectious disease specialist. Said Josh Schiff.

To speed up vaccination, a report suggests that the U.S. should now consider dropping a second dose for the two-dose vaccines produced by Pfizer / Bioentech and Modern. Infectious Disease Research and Policy According to a recommendation made by Mike Osterholm of the University of Minnesota and his colleagues, people over the age of 65 should proceed because they are extremely susceptible to serious disease and death.

The group called on the FDA and CDC vaccine consultants to quickly call and determine whether the data support the group’s recommendations, including postponing the second vaccine dose after the next vaccine.

The report says there is a narrow and quickly closed window of opportunity to use the vaccine more effectively and prevent thousands of serious cases, hospital admissions and potential deaths in the coming weeks and months.

Dr. Officials, including Anthony Fauci, said the U.S. Continuing to vaccinate people from both days and is close to the recommended schedule, Foki told CNN earlier this week. “Science points out that we continue beyond what we know. Clinical trials.”

A pharmacist fills a syringe with a dose of Pfizer's Covid-19 vaccine this month at the P-Five Community Vaccination Center in Valley Stream, New York.

Preliminary research raises concerns about variants in California

More than 1,900 cases of the coronavirus strain have been reported for the first time in the UK, South Africa and Brazil, CDC data show.

Most of those cases – about 1,881 – are of the B..1.1.7 variant pertaining to experts and the CDC has previously warned that it could become the main type by next month.
Lab studies suggest Pfizer, modern vaccines may protect against coronavirus variant

Meanwhile, two studies that are coming out soon also raise concerns about the variant’s impact in California.

Studies indicate that the variable can cause not only more infectious but also more serious disease. But the research is in its very early stages, has not been published or peer-reviewed and needs more work, the researchers stressed.

A team from the University of California, San Francisco tested samples of the latest outbreak of the virus across the state and found that it was becoming very common: while it was not found in any samples in September, it was found by the end of January. Half of the samples.

The researchers also found some evidence that the variable was more dangerous, a report said, adding that they observed “disease severity”, which “increased the risk of requiring high oxygen.”

The second team at UNIDOS en Salud – a volunteer-led collaboration between UC San Francisco and other groups providing rapid Covid-19 testing in the San Francisco Mission District – tested more than 8,800 people in January and tested the virus in more than 630 people, respectively. They also saw rapid growth in variants.

The FDA may store Pfizer vaccines on a standard basis

Concerned about variables, U.S. Officials continue to work to increase vaccinations.

The New York Times reported Tuesday that the FDA plans to authorize Pfizer’s request, allowing the vaccine manufacturer to store its vaccines at regular freezer temperatures instead of the currently required ultra-cold level.

Data released to the FDA by Pfizer and its partner Bioentech on Friday show that its vaccine can be safely stored at temperatures higher than those currently required for long-term storage. The Times cited two sources familiar with the companies, who asked not to be named, saying the FDA informs companies that it will fix the request.

Pfizer, Moderna, Jammu and JA Total 240 million Covid - 19 vaccine doses by end of March

The move could ease logistics not only for companies, but also for the federal government, states and other groups that are working to distribute those vaccines.

Part of that news comes at a time when Pfizer and Moderna have promised to make a combined total of 220 million doses available for shipment by the end of March.

About 55 million Covid-19 doses have been sent to the U.S. government, Moderna said Wednesday. In addition, about 33 million doses have been produced, packed in vials and are in the final stages of production and testing prior to release, the company said in a statement.

Moderna also announced that it has designed an updated version of its vaccine to help fight the South African coronavirus variant. The initial dose for clinical studies is U.S. Have been sent to national health institutions.

The new moderne vaccine, called MRNA-1273.351, will be evaluated as a booster shot for people who do not have the virus and have not yet been vaccinated.

Meanwhile, Johnson and Johnson, who could get green light for their own Covid-19 vaccine from the FDA this weekend, have promised to make 20 million doses available within the same timeframe.

According to an FDA briefing document released Wednesday, Johnson & Johnson’s vaccine appears to be working better than the first known data in South Africa.

The FDA said the vaccine showed a 64% effectiveness rate in South Africa – seven points higher than reports reported in interim company data in January. Since then, Johnson and Johnson have made additional sequences and determined that his analysis from South Africa may include more such cases.

So far, about 44.5 million Americans have received at least the first dose of the Covid-19 vaccine, according to CDC data. Just over 6% of the U.S. population – more than 19.8 million – have been fully vaccinated.

The supply of Covid-19 vaccine doses allocated to states and retail pharmacies is growing by nearly 70%, from 8.6 million doses in January to 14.5 million doses this week, Zints said Wednesday.

One of the many challenges states face when it comes to getting weapons is racial inequality.

Officials in California said the use of the access code distributed by outsiders would change the statewide Covid-19 vaccine-appointment system used by outsiders to protect vaccines.

Recent data show that residents of Black and Latino collectively received 19% of the state’s vaccine dose combined, while California’s Covid-19 accounted for about 60% of the cases. In contrast, White residents have been given a 32.7% vaccine dose while the state has about 20% of cases.

CNN’s John Bonifield, Maggie Fox, Sarah Moon, Cherry Mossberg, Amanda Seeley and Michael Nedelman contributed to the report.